Polyanionic polymer adjuvants for Haemophilus influenzae B saccharide vaccines
AssigneeGlaxosmithkline Biologicals SA
InventorsNathalie Marie-Josephe Garcon, Dominique Lemoine, Florence Emilie Jeanne Francoise Wauters
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of reducing flocculation in an immunogenic composition, where said immunogenic composition comprises (a) Haemophilus influenzae B capsular polysaccharide or oligosaccharide (PRP) and (b) at least one non-PRP antigen. The invention further relates to kits comprising (i) a first composition comprising a Haemophilus influenzae B capsular polysaccharide or oligosaccharide (PRP) and a polyanionic polymer, and (ii) a second composition comprising a non-PRP antigen adsorbed onto an adjuvant with a zero point charge greater than 8.
Claims30
A method of reducing flocculation in an immunogenic composition, where said immunogenic composition comprises (a) Haemophilus influenzae B capsular polysaccharide or oligosaccharide (PRP) and (b) at least one non-PRP antigen, said method comprising the steps of:
- (i) providing a first composition comprising a non-PRP antigen adsorbed onto an adjuvant with a zero point charge greater than 8;
- (ii) adding to said first composition poly-L-glutamic acid (PLG) or poly-L-aspartic acid (PLA) or a salt thereof, to provide a second composition;
- and
- (iii) adding Haemophilus influenzae B capsular polysaccharide or oligosaccharide (PRP) to said second composition to provide a final immunogenic composition.
A method of reducing flocculation in an immunogenic composition, where said immunogenic composition comprises (a) Haemophilus influenzae B capsular polysaccharide or oligosaccharide (PRP) and (b) at least one non-PRP antigen, said method comprising the steps of:
- (i) providing a first composition comprising a non-PRP antigen adsorbed onto an adjuvant with a zero point charge greater than 8;
- (ii) adding to said first composition a second composition comprising Haemophilus influenzae B capsular polysaccharide or oligosaccharide (PRP) and poly-L-glutamic acid (PLG) or poly-L-aspartic acid (PLA) or a salt thereof, to provide a final immunogenic composition.
Dependencies are inferred from the claim text.